Molecular Screening for Cancer Treatment Optimization

Molecular Screening Analysis Used as Decision Tool for Targeted Molecular Treatment

The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival compared to the previous treatment line.

The secondary objectives are to investigate clinical practical feasibility of such technics, to potentially improve the overall survival of patients and to describe molecular portrait of Phase 1 candidates.

Inclusion Criteria:

• Solid tumors ; Stade IV ; Local relapse or metastatic ; Uncurable
• Age > 6 months
• PS 0/1 or Lansky play scale >= 70%
• Minimum one treatment line, no limit in the prior number of treatment line
• Evaluable or measurable disease

Exclusion Criteria:

• Life expectancy < 3 months
• Carcinomatous meningitis
• Symptomatic or progressive radiologic brain metastasis for non-CNS tumors
• Polynuclear neutrophil < 1 x 10^9/L
• Platelets < 100 x 10^9/L
• Hemoglobin < 90 g/L
• ALT/AST > 2.5 N
• bilirubin > 1.5 N
• Creatinine >1.5 N
• Calcemia > ULN
• Phosphate > ULN
• Coagulation anomaly non-indicated for biopsy